Scholarlink

Background <p>Neurofilament light(NfL) and glial fibrillary acidic protein(GFAP) are associated with disease activity in multiple sclerosis(MS), however use in monitoring remains limited. The ability of these biomarkers to detect disease activity upon treatment discontinuation was studied.</p> Methods <p>Long-term stable relapse-onset MS patients were to continue or discontinue their first-line disease-modifying therapy(DMT) to study the safety of DMT discontinuation(DOT-MS trial NCT04260711). “Significant” disease activity was defined as clinical relapse, ≥3 new lesions or ≥2 contrast-enhancing lesions. MRI and sampling were performed at baseline, month 3, 6, 12, 18 and 24. Associations of delta biomarker levels and NfL z-score(age and body mass index derived) with “significant” disease activity were tested. Cut-off values for biomarkers to detect disease activity were calculated.</p> Results <p>45(50.5%) participants discontinued their DMT. Eight(all discontinued DMT) had “significant” disease activity, which was associated with an increase in NfL levels(OR:1.13 [1.03–1.33], <i>p</i>&#xa0;=&#xa0;0.04) and NfL <i>z</i>-scores(OR:2.17 [0.98–5.22], <i>p</i>&#xa0;=&#xa0;0.06), but not with GFAP(<i>p</i>&#xa0;=&#xa0;0.52). Delta NfL had the highest ability to detect “significant” disease activity(AUC:0.88 [0.76–0.99]), with the best calculated cut-off of 46.4% increase(AUC:0.68, sensitivity 0.57, specificity 0.96).</p> Discussion <p>NfL may be useful to identify, but not predict, disease activity after DMT discontinuation in MS. GFAP levels were not discriminatory for disease activity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月23日

查看全文
  • W. H. Fung,
  • M. H. J. Wessels,
  • E. M. E. Coerver,
  • J. de Beukelaar,
  • W. H. Bouvy,
  • L. R. Canta,
  • O. H. H. Gerlach,
  • E. Hoitsma,
  • E. L. J. Hoogervorst,
  • B. A. de Jong,
  • N. F. Kalkers,
  • Z. L. E. van Kempen,
  • H. Lövenich,
  • C. E. P. van Munster,
  • B. W. van Oosten,
  • J. Smolders,
  • A. Vennegoor,
  • E. M. P. E. Zeinstra,
  • M. Barrantes-Cepas,
  • G. Kooij,
  • M. M. Schoonheim,
  • B. I. Lissenberg-Witte,
  • B. Moraal,
  • F. Barkhof,
  • B. M. J. Uitdehaag,
  • J. Mostert,
  • C. E. Teunissen,
  • J. Killestein,
  • E. M. M. Strijbis

摘要

Background

Neurofilament light(NfL) and glial fibrillary acidic protein(GFAP) are associated with disease activity in multiple sclerosis(MS), however use in monitoring remains limited. The ability of these biomarkers to detect disease activity upon treatment discontinuation was studied.

Methods

Long-term stable relapse-onset MS patients were to continue or discontinue their first-line disease-modifying therapy(DMT) to study the safety of DMT discontinuation(DOT-MS trial NCT04260711). “Significant” disease activity was defined as clinical relapse, ≥3 new lesions or ≥2 contrast-enhancing lesions. MRI and sampling were performed at baseline, month 3, 6, 12, 18 and 24. Associations of delta biomarker levels and NfL z-score(age and body mass index derived) with “significant” disease activity were tested. Cut-off values for biomarkers to detect disease activity were calculated.

Results

45(50.5%) participants discontinued their DMT. Eight(all discontinued DMT) had “significant” disease activity, which was associated with an increase in NfL levels(OR:1.13 [1.03–1.33], p = 0.04) and NfL z-scores(OR:2.17 [0.98–5.22], p = 0.06), but not with GFAP(p = 0.52). Delta NfL had the highest ability to detect “significant” disease activity(AUC:0.88 [0.76–0.99]), with the best calculated cut-off of 46.4% increase(AUC:0.68, sensitivity 0.57, specificity 0.96).

Discussion

NfL may be useful to identify, but not predict, disease activity after DMT discontinuation in MS. GFAP levels were not discriminatory for disease activity.